1. Home
  2. BTAI vs LIVE Comparison

BTAI vs LIVE Comparison

Compare BTAI & LIVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$0.84

Market Cap

27.7M

Sector

Health Care

ML Signal

HOLD

Logo Live Ventures Incorporated

LIVE

Live Ventures Incorporated

HOLD

Current Price

$9.59

Market Cap

32.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTAI
LIVE
Founded
2017
1968
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Specialty Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
27.7M
32.7M
IPO Year
2018
1998

Fundamental Metrics

Financial Performance
Metric
BTAI
LIVE
Price
$0.84
$9.59
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$23.00
N/A
AVG Volume (30 Days)
1.2M
8.0K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
75.63
158.14
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$197.82
N/A
Revenue Next Year
$910.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$8.50
52 Week High
$8.08
$25.42

Technical Indicators

Market Signals
Indicator
BTAI
LIVE
Relative Strength Index (RSI) 42.27 43.00
Support Level $0.74 $8.92
Resistance Level $1.39 $11.70
Average True Range (ATR) 0.06 0.71
MACD 0.01 -0.09
Stochastic Oscillator 65.37 15.73

Price Performance

Historical Comparison
BTAI
LIVE

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About LIVE Live Ventures Incorporated

Live Ventures Inc is a holding company of diversified businesses. It acquires and operates companies with a history of earnings power across five segments: Retail-Entertainment, Retail-Flooring, Flooring Manufacturing, Steel Manufacturing, and Corporate & Other. Retail-Entertainment offers new and pre-owned movies, video games, music, books, comics and collectibles through an integrated buy-sell-trade model. Retail-Flooring is a retailer and installer of flooring, carpeting, and countertops, serving consumers, builders, and contractors. Flooring Manufacturing produces and distributes carpet and hard-surface flooring. Steel Manufacturing engages in steel production and fabrication, generating the majority of revenue. Corporate & Other covers corporate costs and legacy products and services.

Share on Social Networks: